Remove journals pharmaceutical-executive
article thumbnail

The Stories That Shine

PharmExec

As someone who’s worked in pharma journalism for many years, there’s something extraordinary to hear about the why for individuals.

article thumbnail

Digital Learning Programs Webinar

Impetus Digital

She has a wide range of leadership experiences as a business development leader from small to big pharmaceutical companies. She went to school at Brock University for Biological Sciences and later completed a post-graduate degree in International Business Management.

Education 119
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

First treatment recommended for infants with Wolman Disease

European Pharmaceutical Review

NICE’s recommendation means that “babies born with Wolman Disease and their parents access to a new treatment option,” Bob Stevens, Group Chief Executive of the MPS Society commented. Evidence of successful long-term management of the disease was reported in a case study published last year in the Canadian Liver Journal.

article thumbnail

First pill for desmoid tumours approved

European Pharmaceutical Review

The FDA’s approval of Ogsiveo is based on results from the Phase III DeFi clinical trial , which were published this year in the New England Journal of Medicine. The post First pill for desmoid tumours approved appeared first on European Pharmaceutical Review. Patients were randomised to receive 150mg of Ogsiveo or placebo. .

article thumbnail

Novel antibody therapeutic demonstrates potential in GVHD

European Pharmaceutical Review

. “[It] is the first investigational chronic GVHD treatment to target inflammation and fibrosis through the inhibition of disease associated macrophages,” stated Michael A Metzger, Chief Executive Officer of Syndax Pharmaceuticals. Phase I/II data for axatilimab in GVHD has been published in the Journal of Clinical Oncology.

article thumbnail

The ins and outs of the life sciences: top hires for October 2022 

pharmaphorum

With more than a decade of experience leading and scaling managed care organisations, Grabski is a seasoned business leader and finance executive. He has also served as VP of Strategy and Execution, primarily responsible for adapting UHC’s Medicare Advantage business to the changes from the ACA. billion in revenue and 300 FTEs.

article thumbnail

Novel drug delivery method shows promise in Alzheimer’s

European Pharmaceutical Review

The post Novel drug delivery method shows promise in Alzheimer’s appeared first on European Pharmaceutical Review. Focused ultrasound therefore has “great promise for improving drug delivery to the brain” he added. Yet several barriers in the body must be overcome to reach its target site, such as the blood-brain barrier.